Although prospective validation is required, serum cytokine profiling including IL-18, S100A9 and soluble p53 and probably other factors associated with inflammasome activation may represent an approach to identify and select anemic patients with lower risk MDS most likely to benefit from asunercept treatment. Here, TP53 is linked to myelodysplastic syndrome.